Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.50 |
| ▸ | VCP | P55072 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369459 | 0.87 | PARP1 (0.48) | PARP1HRH3 | |
| SCHEMBL1382081 | 0.82 | PARP1 (0.67) | PARP1HRH3 | |
| SCHEMBL3231932 | 0.82 | VCP (0.58) | HRH3TLR9TLR8TLR7VCP | |
| SCHEMBL4873456 | 0.80 | HRH3 (0.46) | PARP1HRH3TLR9TLR8TLR7 | |
| SCHEMBL4413051 | 0.78 | DYRK1A (0.64) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL3369864 | 0.78 | PARP1 (0.80) | PARP1 | |
| SCHEMBL3369791 | 0.77 | PARP1 (0.61) | PARP1HRH3TLR9TLR8TLR7 | |
| SCHEMBL6016999 | 0.75 | PARP1 (0.50) | PARP1HRH3 | |
| SCHEMBL3962662 | 0.74 | HRH3 (0.51) | HRH3TLR9TLR8TLR7VCP | |
| SCHEMBL31154217 | 0.73 | HRH4 (0.52) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636216-B1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-7741341-B2 | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-22 | — | — | US | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479676-A1 | Benzimidazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | PARP1 371/4885HRH3 310/4885TLR9 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.